EFFECTS OF EVOLOCUMAB ON LIPOPROTEIN PARTICLES AND SUBCLASSES IN HYPERCHOLESTEROLEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA SUBJECTS ON STATIN THERAPY

  • Xu R
  • Dias C
  • Peach M
  • et al.
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Background: LDL particle concentrations are associated with cardiovascular disease. Subclasses of lipoprotein particles, defined by size, may have different atherogenic properties. We evaluated the effect of evolocumab (formerly AMG 145) on LDL, VLDL, and HDL particles (LDL-P, VLDL-P, HDL-P), size, and subclass cholesterol content in hypercholesterolemic and HeFH subjects. Methods: Exploratory biomarker samples from a phase 1b study were used. Hypercholesterolemic subjects on low to moderate dose statins received evolocumab ranging from 14 mg (QW) to 420 mg (Q4W) or placebo. Subjects on high dose statins and HeFH subjects received 140 mg evolocumab (Q2W) or placebo. In baseline and post-dose samples, LDL-P, VLDL-P, and HDL-P and size were determined by NMR. Cholesterol of lipoprotein subclasses was measured by VAP. Results: Results from subjects receiving 140 mg evolocumab Q2W or placebo are summarized below: Conclusion: In this study, evolocumab treatment lowered VLDL-P, VLDL-C, LDL-C, and LDL-P, with a significant effect on small LDL-P. HDL-P and HDL-C also trended up. (Table Presented)

Cite

CITATION STYLE

APA

Xu, R., Dias, C., Peach, M., Gao, B., Hamilton, L., Smith, B., … Wasserman, S. (2014). EFFECTS OF EVOLOCUMAB ON LIPOPROTEIN PARTICLES AND SUBCLASSES IN HYPERCHOLESTEROLEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA SUBJECTS ON STATIN THERAPY. Journal of the American College of Cardiology, 63(12), A1378. https://doi.org/10.1016/s0735-1097(14)61378-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free